Neurogene (NGNE) vs Oculis (OCS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Neurogene (NGNE) has outperformed Oculis (OCS) over the past year, gaining 2.6% versus a loss of 56.4%. Over five years, OCS leads with a -11.8% price change compared with -81.6% for NGNE. Oculis is the larger company by market cap ($533.4 million vs $530.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NGNE | OCS |
|---|---|---|
| Share price | $26.50 | $8.66 |
| Market cap | $530.30M | $533.35M |
| 1-day change | +2.44% | +1.88% |
| YTD return | +28.64% | -56.63% |
| 1-year return | +2.59% | -56.42% |
| 5-year return | -81.65% | -11.81% |
| EPS (TTM) | $-5.15 | $-1.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $43.66 | $34.48 |
| 52-week low | $15.93 | $8.30 |
| Distance from 52-week high | -39.30% | -74.88% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +193.89% | +321.36% |
| Average volume | 247.13K | 257.00K |
| Shares outstanding | 20.01M | 61.59M |
| Employees | 131 | 60 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NGNE has outperformed OCS by 59.0 percentage points over the past year.
- The two companies sit in different sectors: Neurogene in Healthcare and Oculis in Health Care.
About Neurogene
NGNE stock →Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Healthcare · Biotechnology · 131 employees
About Oculis
OCS stock →Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.
Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees
NGNE vs OCS FAQ
Which is bigger, Neurogene or Oculis?
Oculis (OCS) is larger, with a market capitalization of $533.35M compared with $530.30M for Neurogene (NGNE).
Which stock has performed better over the past year, NGNE or OCS?
NGNE returned +2.59% over the past 12 months, compared with -56.42% for OCS (price return, excluding dividends). Past performance does not predict future results.
Are Neurogene and Oculis in the same industry?
No. Neurogene is in the Healthcare sector, while Oculis is in Health Care.